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patients receiving 45 mg and 76.9% of those receiving 90 mg
experienced a reduction of 5 points in DLQI score, signifying an
important difference, compared with 21.4% for placebo (each
p < 0.001 versus placebo). All DLQI scores improved from
baseline to Week 12 in each active treatment group compared
with placebo (each p < 0.001 versus placebo). Improvements
were observed in clinical parameters, HADS, and WLQ.
CONCLUSION: Ustekinumab resulted in signiﬁcant and clini-
cally meaningful improvements in QOL within 1 month after
starting treatment; improvements at Week 12 were maintained
through Week 24. Improvements were also observed in anxiety,
depression, and work limitations.
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OBJECTIVE: Patient–reported outcome measures, in particular
those evaluating health-related quality of life (HrQoL) , have
been proposed as a mean of facilitating doctor-patient commu-
nication. While these measures are commonly included in clinical
research studies, their use in clinical practice is still quite limited.
Our objective is to assess HrQoL in a dermatological clinic daily
routine and to develop an appropriate and effective reporting
tool for health personnel. METHODS: First phase: patients
were invited to complete the Skindex-29, GHQ-12, and SF-36
questionnaires. Scores were returned to the clinical staff. Second
phase: the patients’ medical records were reviewed to verify
which issues (e.g., pain, itch, bleeding, sleep loss, functional
limitations, fatigue) highlighted by the questionnaires were
recorded/neglected by physicians. Third phase: we developed a
check list (presence/absence) of symptoms, emotions or func-
tional problems to be ﬁlled by health personnel to complete the
routine clinical records. RESULTS: For 170 participants (63%
males, 35% age > 64 years), feedback forms were provided
within three hours from data collection. We analyzed data for
126 patients with the most common conditions: psoriasis
(n = 40), dermatitis (n = 30), leg ulcers (n = 13), pemphigus
(n = 22), cutaneous lymphoma (n = 21). Overall, sensitivity of
medical records in identifying patients’ problems ranged from
zero for most issues (including sleep loss, sex life, bleeding), to
3% for burning, 10% for depression, 15% for pain, and 35% for
itching. A 30-item checklist (a synthesis of the three question-
naires) was developed and tested in 100 patients who completed
their Skindex-29 questionnaire. The sensitivity and speciﬁcity of
physicians’ records increased for each issue, ranging from 7%
(humiliation) to 81% (itching). CONCLUSION: The routine
assessment of HrQoL in dermatology is feasible. The checklist
induced the staff to report on medical records often-neglected
patients’ problems. The checklist increased substantially the sen-
sitivity of physicians in identifying patients’ problems.
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OBJECTIVE: Cutaneous lymphomas may have a profound
impact on patients’ health-related quality of life (HRQoL) and
psychological well-being. A detailed investigation of HRQoL,
analyzing its correlation with clinical variables and biological
parameters, has not been done before. METHODS: The study
population consisted of patients with cutaneous T- cell (CTCL)
or B-cell lymphoma (CBCL), consecutively recruited in the
outpatient and the inpatient clinics of an Italian hospital. Data
was collected using a dermatology-speciﬁc questionnaire, the
Skindex-29 (symptoms, emotions, and functioning scales), and
an oncology-speciﬁc questionnaire, the EORTC QLQ-C30 (15
scales, concerning physical and emotional aspects). RESULTS:
Of 95 patients, there were 24 patients with CBCL, 59 with
mycosis fungoides (MF), and 12 with Sézary syndrome (SS). The
most frequent problems appearing from the EORTC QLQ-C30
analysis were fatigue, pain, and insomnia. The differences among
hystotypes were particularly high in the global health status and
emotional functioning scales, with a worse HRQoL in patients
with SS, followed by MF, and CBCL. HRQoL impairment in all
hystotypes was higher in women than in men, in patients with
probable anxiety or depression, and when the disease worsened.
The multivariate analysis of the independent role of each variable
conﬁrmed these results. The highest prevalence of probable
anxiety or depression was observed in patients treated with sys-
temic steroids (60%) and interferon (50%). CONCLUSION:
The detailed evaluation of HRQoL and psychological problems
in patients with cutaneous lymphomas, and their relationship
with clinical variables, may give important information on the
course of the disease as well as the possible effect of treatment.
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OBJECTIVE: To develop an internationally validated Quality of
Life (QoL) instrument speciﬁc to cosmetology and personal
appearance. This instrument will allow to measure the impact
of the use of cosmetic products in various QoL dimensions.
METHODS: Several studies have demonstrated the positive
impact of cosmetic products in dimensions. However, no speciﬁc
instrument exists to assess the main QoL dimensions in the
general population of cosmetic users. The BeautQol question-
naire is designed to be a multi-dimensional, self-administered
QoL questionnaire developed simultaneously in 13 countries.
The questionnaire focuses on concerns identiﬁed by users using
cosmetic products or cosmetic techniques. Semi directive inter-
views were carried out simultaneously in 10 countries with a
total of 309 users by clinical psychologists in France (32), UK
(18), Germany (46), Spain (27), Sweden (19), Russia (16), USA
(53), Brazil (32), Japan (48), and China (18). Interviews have
been audio or video recorded and reported in a standard format
report. Interviews were analyzed both semantically and using
text-mining techniques (Alceste software). RESULTS: From the
analysis of the 10 interview country reports, 61 items were
selected leading to 61 questions in the prototype questionnaire
describing major domains such as well being, self esteem, social
life, love life, sexual life, conﬁdence, happiness, image, status,
emotion, seduction, success, vitality, charisma, motivation, joy,
fun, dignity, etc. Three additional countries joined the project
(India, South Africa and Italy). The acceptability study is cur-
rently in progress with 650 users. The planned validation study
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